

## NUZYRA - (EQ 150MG BASE ; Tablet)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | OMADACYCLINE TOSYLATE   | <b>Innovator</b>            | Paratek Pharms      |
| <b>Dosage</b>                | EQ 150MG BASE ; Tablet  | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | None  | <b>Known Para IV Filers</b> | None                |
| <b>Other ANDA developers</b> | More Than 5   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms: • Community-acquired bacterial pneumonia (CABP) • Acute bacterial skin and skin structure infections (ABSSSI). |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## NUZYRA - (EQ 100MG BASE/VIAL ; Powder)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | OMADACYCLINE TOSYLATE   | <b>Innovator</b>            | Paratek Pharms      |
| <b>Dosage</b>                | EQ 100MG BASE/VIAL ; Powder   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | None  | <b>Known Para IV Filers</b> | None                |
| <b>Other ANDA developers</b> | Less Than 5   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms: • Community-acquired bacterial pneumonia (CABP) • Acute bacterial skin and skin structure infections (ABSSSI). |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.